PACS Group, Inc.
In the published model solve dated 2026-Q2, anchored at $45.63, PACS Group, Inc. (PACS) is priced for +10.4% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
- PACS is a fast-growing skilled-nursing operator, and the right way to read it is as a roll-up still in expansion mode, not a mature business. At $36.62 only the growth method reaches the price; the static frames all say richly valued, which is the signature of a compounding bet. - The numbers have recovered after a scare. Q1 2026 revenue rose 11.2% to $1.42 billion, occupancy improved to 90.9%, and net income jumped, but the company also restated 2024 results, removing as much as $65 million o
Is PACS overvalued? See what's priced in →
208 institutional managers reported holding PACS in 13F filings for the quarter ended 2026-03-31. Together they hold about 29% of the company; the top 10 hold 20%. 66 opened new positions that quarter. Held by Cohen & Steers, FMR (Fidelity), Vanguard Group, among others. On the short side, 4.4M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (5.2 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
Open-market insider buys at PACS over the trailing three years: 2024: 1 buy totaling $10k; 2025: 1 buy totaling $500k. 14 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
PACS's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2024-08-13 | +17.3% | +6.6% |
| 2025-11-20 | +81.0% | +34.3% |
| 2026-02-28 | -7.0% | -9.6% |
| 2026-05-12 | +22.3% | pending |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
PACS's latest 8-K filings: 2026-08-04 (items 2.02, 9.01); 2026-06-15 (items 5.07); 2026-05-11 (items 2.02, 9.01); 2026-04-27 (items 5.02, 7.01, 9.01); 2026-03-05 (items 5.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.